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Background: Adiponectin is a major regulator of glucose and lipid homeostasis by its insulin sensitizer properties.
Since decreased insulin sensitivity is linked to metabolic syndrome (MS), decreased adiponectin levels may be
related to its development. The purpose of the study was to investigate the relationship between adiponectin
levels and MS.
Methods: Firstly, we cross-sectionally examined subjects with or without MS submitted to an oral glucose tolerance
test at Hospital de Clínicas de Porto Alegre (n = 172). A replication analysis was performed in subjects (n = 422)
undergoing cardiac angiography at Hospital São Paulo. Subchronic inflammation (US-CRP), coagulation marker
(fibrinogen), insulin sensitivity and resistance (Matsuda ISI and HOMA-IR) were estimated. Plasma total and high
molecular weight (HMW) adiponectin were measured.
Results: Total and HMW adiponectin levels were lower in MS subjects (P < 0.05). Total adiponectin levels were
lower in the presence of high waist circumference, low HDL-cholesterol and elevated triglyceride criteria in both
samples and by elevated blood pressure and glucose criteria in Porto Alegre. HMW adiponectin levels were lower
in the presence of low HDL-cholesterol, elevated triglycerides, and glucose criteria. Total adiponectin levels were
positively related with HDL-cholesterol and ISI Matsuda, negatively related with waist circumference, glucose,
triglycerides, HOMA-IR, and US-CRP and not related with blood pressure. While adjusting for sex and age, increased
adiponectin levels remained associated with a reduced prevalence ratio for MS in both cohorts (P = 0.001).
Conclusions: Adiponectin levels decreased with increasing number of MS criteria, and it is in part determined by
its relationship with HDL, triglycerides and abdominal adiposity.
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Obesity is a major public-health problem worldwide. It
has been associated with the development of metabolic
syndrome (MS) [1] which is an interrelated cluster of
risk factors for cardiovascular disease (CVD) and type 2
diabetes [2,3] such as hyperglycemia, raised blood pres-
sure, elevated triglyceride levels, low high-density lipopro-
tein cholesterol levels, and central obesity [4]. Data from
the NHANHES study has shown that 22.9% of United
States adult population had MS in 2009/10 [5].* Correspondence: anize.frankenberg@gmail.com
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article, unless otherwise stated.The growing rates of this obesity-related syndrome
have spurred the search for greater insight about mecha-
nisms contributing to the development of MS, especially
those reflecting a dysfunction of adipose tissue, which
probably plays a major role in its development [6].
Adiponectin, a hormone expressed in adipose tissue and
encoded by the ADIPOQ gene (chromosome 3q27), plays
an important role in regulating insulin sensitivity, glu-
cose and lipid metabolism besides anti-inflammatory
and anti atherogenic properties [7]. Its high molecular
weight (HMW) isoform is the major responsible for
these functions [8]. In the presence of obesity, adipo-
nectin release is down regulated resulting in reduced
circulating levels [9].d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and HMW adiponectin levels and the presence of MS
we measured its levels in two different cohorts. We were
also interested in finding out which MS components are
mostly related to adiponectin levels. Additionally, we an-
alyzed how insulin resistance, sensitivity and subchronic
inflammation were related to adiponectin levels.
Methods
Subjects
In order to determine the relationship between MS and
adiponectin, we undertook a two-stage study using data
from two cohorts. In the first stage, the relationship be-
tween adiponectin and MS was assessed in consecutive
subjects who were referred for ambulatory care in the
Metabolism Unit of Hospital de Clínicas de Porto Alegre,
Federal University of Rio Grande do Sul (n = 172), whose
glycemic status was not previously defined. Exclusion cri-
teria included clinically significant autoimmune diseases,
uncompensated hypo or hyperthyroidism, malignant dis-
ease that may affect 5-year survival, stage IV or V chronic
kidney disease, AIDS, pregnancy/lactation, dementia, cir-
rhosis, hepatitis, alcohol or illicit drug abuse, glucocortic-
oid or anti-retroviral treatment, and malnutrition. The
protocol was approved by the institutional review board of
Hospital de Clínicas de Porto Alegre and the subjects pro-
vided written informed consent.
In order to confirm the relationship between adipo-
nectin levels and MS we performed a second stage study
(replication analysis) with data from the Endocrinology
and Cardiovascular Units of the hospital of the Federal
University of São Paulo (São Paulo cohort, UNIFESP)
of 422 consecutive subjects who had complete assess-
ment of MS criteria and underwent cardiac angiogra-
phy for investigation of coronary heart disease, according
to an indication of their clinician as previously des-
cribed [10]. Exclusion criteria included creatinine clea-
rance <50 mL/min, abnormal thyroid function, presence
of active inflammatory disease and neoplasia. The protocol
was approved by the institutional committee of ethical
practice of UNIFESP and subjects provided written in-
formed consent.
Study procedures and assays
Subjects from the Porto Alegre and the São Paulo co-
horts underwent a standard evaluation which included
medical history, physical examination and anthropo-
metric measurements. Ethnicity was classified based on
self-reported skin color and recorded as white and non
white. Current smoking was defined by active consump-
tion in the last three months. Habitual alcohol con-
sumption was accessed by a yes or no question. Subjects
were classified as physically active if they practiced
moderate-intensity activity for at least 150 minutesper week. Body weight was recorded in light clothing
without shoes. Height was measured on a stadiometer.
BMI was calculated by weight (kg)/height (m2) [11]. Waist
circumference was taken at the midpoint between the
lower costal margin and the iliac crest measured to the
nearest 0.5 cm.
In the Porto Alegre cohort, blood pressure measure-
ments were performed one week after withdrawal of all
antihypertensive medications whereas in the São Paulo
cohort subjects were not withdrawal of medications in
use. Office blood pressure were measured by the arm
blood pressure oscillometric monitor device OMRON®
(H-003D) with cuff adjusted for arm circumference while
the participant was seated, in the right arm three times by
auscultation, and the mean of the last two measurements
was used to estimate systolic and diastolic arterial blood
pressure in both cohorts. For a better understanding
of the relationship between adiponectin and arterial
blood pressure, ambulatory 24-h blood pressure moni-
toring (ABPM) was performed by oscillometry (Spacelabs
90207), with a 15-min interval during the daytime and a
20-min interval during the nighttime in 129 subjects from
the Porto Alegre cohort. Subjects were advised to main-
tain their usual daily activities. Sleep time was recorded as
the period between the time when the patient went to bed
and the time when the patient woke up the next morning.
The means of 24-h, daytime, and nighttime systolic and
diastolic blood pressure were recorded.
Blood samples were drawn after an overnight fast for
analysis of lipids (total, HDL cholesterol, and triglyce-
rides), glycated hemoglobin (HbA1c), insulin, and total
adiponectin in subjects from both cohorts. HMW adipo-
nectin was measured in blood samples of subjects from
the São Paulo cohort. Ultra-sensitive C-reactive protein
(us-CRP) and fibrinogen were measured in blood sam-
ples of subjects from the Porto Alegre cohort. Subjects
from the Porto Alegre cohort were also submitted be-
tween 8:00 and 9:00 AM to a 75-g oral glucose tolerance
test (OGTT) in which both glucose and insulin were
measured at 0, 30, 60, 90 and 120 minutes. All subjects
were classified according to glucose tolerance status [12]
and presence of MS [4].
Assays
Serum total and HDL-cholesterol, triglycerides, insulin,
HbA1c, US-CRP and fibrinogen were measured in the
Clinical Pathology Unit. Cholesterol and triglycerides
were determined by means of an enzymatic method
(Ádvia 1800); insulin by chemiluminescence (Centaur
XP); HbA1c by high performance liquid chromatography
(Tosoh Plus); US-CRP by turbidimetry (Ádvia 1800) and
fibrinogen by coagulometric method (BCS).
In the Porto Alegre cohort, plasma samples for adi-
ponectin were analyzed in duplicate by using ELISA kits
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3.84% and inter-assay CV < 5.50%). Plasma adiponectin
study samples respectively presented an intra and inter-
assay CV of 2.99% and 4.26%. In the São Paulo cohort,
total and HMW adiponectin levels were measured in plas-
ma samples using commercial ELISA kits (EZHADP-61 K
and EZHMWA-64 K, respectively, Millipore, Saint Charles,
MO). Intra- and interassay CV were respectively 7.4% and
10.6% for total adiponectin and 3.41% and 9.0% for HMW
adiponectin.Classification of metabolic syndrome
MS was defined as the presence of three out of five cri-
teria described below: high waist circumference (≥ 80 cm
for women and ≥ 94 cm for men); elevated triglyceride
levels (≥ 150 mg/dL [1.7 mmol/L]) or drug treatment
for elevated triglycerides levels; reduced HDL-cholesterol
(<40 mg/dL [1.0 mmol/L] for men and <50 mg/dL
[1.3 mmol/L] for women) or drug treatment for reduced
HDL-cholesterol levels; elevated blood pressure (systolic ≥
130 mm Hg or diastolic ≥ 85 mm Hg) or antihypertensive
drug treatment; and elevated glucose (fasting plasma
glucose ≥100 mg/dL [6.1 mmol/L]) or drug treatment
for hyperglycemia according to Consensus Societies/Joint
Interim Statement [4]. Since subjects from the Porto
Alegre cohort were submitted to the OGTT, we have
also used the 2 h-plasma glucose criteria for impaired
glucose tolerance (≥ 140 mg/dL [7.8 mmol/L]) in order to
define the glucose criteria [4].Classification of glucose tolerance
Based on fasting and 2 h-plasma glucose concentrations,
subjects from the Porto Alegre cohort were categorized
according to the American Diabetes Association criteria
as having normal glucose tolerance (NGT: fasting plasma
glucose [FPG] <100 mg/dL [6.1 mmol/L] and 2 h-plasma
glucose level <140 mg/dL [7.8 mmol/L]); impaired fast-
ing glucose (IFG; FPG 100-125 mg/dL [6.1–6.9 mmol/L]
and 2 h-plasma glucose level <140 mg/dL [7.8 mmol/L]),
or impaired glucose tolerance (IGT; FPG <100 mg/dL
[6.1 mmol/L] and 2 h-plasma glucose level 140-199 mg/dL
[7.8–11.0 mmol/L]) and diabetes (FPG ≥126 mg/dL [7.0
mmol/L] and/or 2-h PG ≥ 200 mg/dL [11.1 mmol/L) [12].
Subjects with IFG and/or IGT were considered to have
prediabetes and this was also used to define the glucose
criteria of the MS. Subjects from the São Paulo cohort
were classified based on fasting glucose as described above
and/or using HbA1c levels according to the American
Diabetes Association criteria as NGT (FPG <100 mg/dL
[6.1 mmol/L] and HbA1c <5.7%); prediabetes (FPG 100-
125 mg/dL [6.1–6.9 mmol/L] and/or HbA1c between 5.7
and 6.4%), and diabetes (FPG ≥126 mg/dL [7.0 mmol/L]
and/or HbA1c ≥ 6.5%).Estimation of insulin sensitivity, insulin resistance,
inflammation and endothelium dysfunction
Indices of insulin sensitivity or insulin resistance were
determined, including: the homeostatic model assess-
ment of insulin resistance (HOMA IR = [fasting glucose
(mmol/L) * fasting insulin (μU/mL)]/22.5) [13] and the
Matsuda insulin sensitivity index (Matsuda ISI) that was
calculated as 10,000/√ [fasting glucose (mmol/L) × fasting
insulin (mU/L)] × [mean glucose ×mean insulin during
OGTT] [14]. Subchronic inflammation was estimated by
US-CRP and coagulation marker by fibrinogen [15,16].
Statistical analysis
Data were expressed as absolute number (%), mean ±
standard deviation (SD) or median (P25-P75). To com-
pare demographic, clinical, and laboratory data utilizing
the presence or the different components of MS, the
chi-square test, independent-samples t test and one-way
ANOVA were used as appropriate. Prevalence of MS
by adiponectin tertiles was compared by chi-square test.
Variables with a non-normal distribution were log trans-
formed before analyses. The significance of the correla-
tions was examined by using the parametric Pearson's
correlation coefficient for normally distributed or log
transformed variables. To test the independent associ-
ation of adiponectin and MS, multivariate regression
analyses were performed using three different Poisson
regression models. Prevalence ratio and 95% CI for con-
tinuous variables are shown for a 1-SD-magnitude in-
crease (equal to 7.063 μg/mL). The first model contained
MS as the dependent variable and age, gender and adipo-
nectin as the independent variables. In the second model,
US-CRP and HOMA-IR were added. In the third model,
HOMA-IR was replaced by ISI-Matsuda into the model.
We did not include as independent variables those that
define a criterion for MS in order to avoid double correc-
tion. A P value or a P for trend < 0.05 was chosen as the
level of significance. Calculations were made by using
SPSS (version 19.0; SPSS Inc, Chicago).
Results
Subjects’ characteristics
Porto Alegre cohort
The Porto Alegre cohort comprised 172 subjects, of
whom 124 (72%) were females. The clinical and labora-
tory characteristics are summarized in Table 1. Subjects
were subdivided by absence (21%) or presence (79%) of
MS. Although these two groups did not differ by gender
distribution, ethnicity, smoking status, alcohol consump-
tion, physical activity, total cholesterol, and fibrinogen
subjects with MS were older and presented higher HbA1c
levels, HOMA-IR, and US-CRP than those without MS.
Prediabetes and type 2 diabetes prevalence were higher in
the presence of MS. BMI, waist circumference, fasting
Table 1 Subjects’ demographic, clinical and laboratory characteristics according to the presence of metabolic
syndrome (MS)
Porto Alegre cohort MS São Paulo cohort MS
Absence Presence P valuea Absence Presence P valuea
N 36 136 - 38 382 -
Female sex 28 (78%) 96 (71%) 0.531 10 (26%) 181 (47%) 0.010
Age (years) 48 ± 12 54 ± 11 0.010 59 ± 12 60 ± 10 0.647
Etnicity (% of white) 28 (78%) 114 (84%) 0.676 20 (51%) 233 (61%) 0.286
Tabagism 5 (14%) 18 (13%) 0.740 26 (67%) 302 (79%) 0.334
Habitual alcohol consumption 3 (8%) 11 (8%) 0.937 5 (13%) 10 (3%) 0.016
Physical activity 0.082 0.061
Sedentary 17 (46%) 79 (58%) 18 (46%) 111 (29%)
Active (≥150 min per week) 19 (54%) 57 (42%) 21 (54%) 271 (71%)
BMI (Kg/m2) 28 ± 6 33 ± 6 - 23 ± 3 29 ± 5 -
Overweight 12 (33%) 48 (36%) - 9 (24%) 130 (34%) -
Obesity 12 (33%) 79 (59%) - 1 (3%) 149 (39%) -
Waist circumference (cm)
Females 91.4 ± 14.2 105.5 ± 12.5 - 80.7 ± 8.0 97.8 ± 12.4 -
Males 101.1 ± 16.8 106.7 ± 11.8 - 84.9 ± 6.2 100.6 ± 1.1 -
Glucose Tolerance Status <0.001 <0.001
Normal Glucose Tolerance 32 (89%) 16 (12%) 20 (53%) 50 (13%)
Prediabetes 1(3%) 76 (56%) 12 (32%) 123 (31%)
Type 2 diabetes 3 (8%) 44 (32%) 6 (16%) 209 (56%)
Fasting plasma glucose (mg/dL) 91 ± 11 114 ± 41 - 100 ± 24 126 ± 47 -
2 h-plasma glucose (mg/dL) 111 ± 43 191 ± 81 - - - -
HbA1c (%) 5.5 ± 0.6 6.4 ± 1.2 0.001 5.7 ± 0.8 6.9 ± 1.6 <0.001
HOMA-IR 1.6 (1.1 – 2.4) 3.3 (1.9 – 4.7) 0.002 0.5 (0.3 – 0.6) 1 (0.6 – 1.6) <0.001
Total cholesterol (mg/dL) 201 ± 41 205 ± 42 0.749 272 ± 48 270 ± 54 0.861
HDL- cholesterol (mg/dL) 55 ± 13 47 ± 12 - 46 ± 12 38 ± 10 -
Triglycerides (mg/dL) 100 ± 40 162 ± 91 - 96 ± 26 163 ± 92 -
US-CRP (mg/L) 1.8 (1.5 – 4.6) 4.0 (5.4 – 8.3) 0.003 - - -
Fibrinogen (mg/dL) 349 (300 – 385) 384 (372 – 412) 0.107 - - -
Systolic Blood Pressure (mm Hg) 125 ± 19 144 ± 22 - 138 ± 24 141 ± 23 -
Diastolic Blood Pressure (mm Hg) 79 ± 11 87 ± 13 - 79 ± 15 80 ± 13 -
Systolic 24-h Blood Pressure (mm Hg) 118.4 ± 12.6 134.3 ± 15.2 0.010 - - -
Diastolic 24-h Blood Pressure (mm Hg) 71.5 [65 – 79.3] 79.0 [70.5 – 87.0] 0.087 - - -
Systolic daytime Blood Pressure (mm Hg) 121.3 ± 12.8 137.9 ± 15.1 0.010 - - -
Diastolic daytime Blood Pressure (mm Hg) 75.0 [68.3 – 83.0] 83.0 [75.0 – 90.0] 0.107 - - -
Systolic nighttime Blood Pressure (mm Hg) 112.3 ± 13.3 126.6 ± 17.0 0.023 - - -
Diastolic nighttime Blood Pressure (mm Hg) 65.6 ± 10.0 71.5 ± 11.9 0.114 - - -
Medicines:
Antihypertensive 8 (22) 68 (52) 0.014 20 (54) 316 (86) <0.001
Statin 3 (9) 23 (18) 0.671 11 (28) 235 (61) <0.001
Hypoglycemic 0 (0) 0 (0) 0.998 9 (23) 85 (20) 0.854
Data expressed as absolute number (%), mean ± SD or median (P25-75). SI conversion factors: triglycerides, mg/dL × 0.01129 = mmol/L; cholesterol, HDL-cholesterol,
and LDL-cholesterol, mg/dL × 0.02586 = mmol/L; glucose, mg/dL × 0.0556 = mmol/L. aP value for comparisons between two groups was tested by χ2 test for categorical
variables or Student’s t test for continuous variables and were adjusted for age and sex by multiple logistic regression analysis. Since the sample was grouped by the
presence of MS, P values were not expressed for comparison of its components (all P values were < 0.05).
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were also greater in subjects with MS. By ambulatory
blood pressure monitoring, 24-h, day and night systolic
blood pressures were also greater in subjects with than
without MS (Table 1).
Plasma adiponectin was lower in the presence of MS
(11.0 [7.9 – 13.7 μg/mL] vs 16.4 [10.2 – 22.7 μg/mL];
median [P25-P75], p < 0.001) (Figure 1A) and decreased
significantly with an increasing number of MS criteria
(Figure 1B). Furthermore, when participants were strati-
fied into three groups by adiponectin tertiles, the preva-
lence of MS decreased from the lowest to the highest
adiponectin tertile (tertile 1 = 89.5%, tertile 2 = 87.9%, and
tertile 3 = 59.6%; P for trend < 0.001).
While comparing by each MS criterion, adiponectin
levels were significantly lower in the presence of fol-
lowing criteria: high waist circumference (12.4 [8.1 –
14.5 μg/mL] vs 18.5 [11.9 – 26.3 μg/mL]; P = 0.002), low0
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To examine the relationship between adiponectin le-
vels and the different MS components, we determined
their correlations. Adiponectin levels were positively cor-
related with HDL-cholesterol (r = 0.452, P < 0.001) and
negatively correlated with waist circumference (r = -0.269,
p < 0.001), fasting glucose (r = -0.289; P = 0.001), and tri-
glycerides (r = -0.252, p < 0.001). There was no significant
correlation between adiponectin concentrations and sys-
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0.383), diastolic 24-h (r = -0.042; P = 0.695), diastolic
daytime (r = -0.030; P = 0.779), and diastolic nighttime
(r = -0.042; P = 0.692) blood pressures.
Furthermore, adiponectin was negatively related to
US-CRP (r = -0.154; P = 0.047) whereas this relation-
ship was not found with fibrinogen (r = -0.048; P = 0.552).
Regarding resistance and insulin sensitivity indexes (ISI),
adiponectin was negatively associated with HOMA-IR
(r = -0.218; P = 0.005) and positively associated with
Matsuda ISI (r = 0.191; P = 0.014).
São Paulo cohort
In order to confirm the relationship between adiponec-
tin levels and MS we performed a second stage study in
422 subjects who were submitted to cardiac angiography
for evaluation of coronary heart disease as indicated by
their clinician, of whom 190 (45%) were females (Table 1).
Subjects were subdivided by absence (9%) or presence
(91%) of MS. Age, ethnicity, smoking status, physical ac-
tivity, and total cholesterol were similar between groups.
However, alcohol consumption was lower in the presence
of MS. As we have already observed in the Porto Alegre
cohort, glucose tolerance decreased whereas HbA1C
and HOMA-IR increased in the presence of MS. BMI,waist circumference, fasting plasma glucose, triglycerides
and blood pressure were greater in subjects with MS as
expected.
Plasma adiponectin had a similar pattern as observed
in subjects from the Porto Alegre cohort. It was lower in
the presence of MS (8.2 [5.5 – 13.8 μg/mL] vs 12.8 [9.0 –
20.5 μg/mL]; median [P25-P75], p = 0.005) (Figure 1A)
and it significantly decreased with an increasing number
of MS criteria (Figure 1B). Furthermore, when participants
were stratified into three groups by adiponectin tertiles,
the prevalence of MS decreased from the lowest to the
highest adiponectin tertile (tertile 1 = 96.4%, tertile 2 =
91.5%, and tertile 3 = 90.8%; P for trend = 0.001).
Comparing according to the presence or absence of
each MS criterion, adiponectin levels were significantly
lower in the presence of following criteria: high waist
circumference (10.4 [7.1 – 12.6 μg/mL] vs 18.5 [11.9 –
26.3 μg/mL]; P = 0.001), low HDL-cholesterol (10.6 [5.5 –
13.7 μg/mL] vs 14.4 [7.8 – 17.2 μg/mL]; P = 0.010), and
elevated triglycerides (6.7 [7.6 – 9.6 μg/mL] vs 10.3 [11.7 –
14.0 μg/mL]; P < 0.001). However, this relationship was
not found with elevated glucose (11 [5.6 – 14.0 μg/mL]
vs 12.3 [5.8 – 15.7 μg/mL]; P = 0.110) and elevated
blood pressure (11.0 [5.7 – 14.1 μg/mL] vs 10.9 [5.5 –
14.5 μg/mL]; P = 0.570).
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and the different MS components, adiponectin concen-
trations were positively correlated with HDL-cholesterol
(r = 0.371; P < 0.001) and negatively correlated with waist
circumference (r = -0.317; P < 0.001), fasting glucose
(r = -0.118; P = 0.015), and triglycerides (r = -0.359;
P < 0.001). Similar to the Porto Alegre cohort, there was
no significant correlation between adiponectin concentra-
tions with diastolic and systolic blood pressures (Figure 2).
HMW adiponectin had similar results as observed with
total adiponectin. It was lower in the presence of MS (4.9
[6.2 – 7.3 μg/mL] vs 7.8 [7.9 – 13.5 μg/mL]; median [P25-
P75], p < 0.001) and it significantly decreased with an in-
creasing number of MS criteria (p < 0.001). Furthermore,
when participants were stratified into three groups by adi-
ponectin tertiles, the prevalence of MS decreased from the
lowest to the highest adiponectin tertile (tertile 1 = 96.2%,
tertile 2 = 91.5%, and tertile 3 = 83.8%; P for trend = 0.007).
Comparing according to the presence or absence of
each MS criterion, HMW adiponectin levels were signi-
ficantly lower in the presence of following criteria: low
HDL-cholesterol (4.9 [6.3 – 7.4 μg/mL] vs 7.7 [7.3 –
11.5 μg/mL]; P = 0.005), elevated triglycerides (4.0 [4.6 –
5.9 μg/mL] vs 6.8 [7.7 – 9.4 μg/mL]; P < 0.001), and
elevated glucose (5.0 [6.4 – 7.5 μg/mL] vs 7.0 [6.7 –
10.6 μg/mL]; P = 0.035). However, this relationship was
not found with high waist circumference (5.0 [6.2 –
7.3 μg/mL] vs 5.9 [7.0 – 10.6 μg/mL]; P = 0.065), and
elevated blood pressure (5.0 [6.5 – 7.7 μg/mL] vs 6.0
[5.8 – 9.3 μg/mL]; P = 0.170).
While analyzing the relationship between adiponectin
and the different MS components, HMW adiponectin
concentrations were positively correlated with HDL-
cholesterol (r = 0.378; P < 0.001) and negatively cor-
related with waist circumference (r = -0.246; P < 0.001),
fasting glucose (r = -0.128; P = 0.008), and triglycerides
(r = -0.320; P < 0.001).
Association between MS and adiponectin levels while
adjusting for possible confounders
Porto Alegre cohort
To confirm the relationship between adiponectin levels
and the presence of MS, we performed three different
multiple Poisson regression models with MS as the de-
pendent variable. In the first model an increment of
1-SD of adiponectin levels was significantly associated
with a lower prevalence ratio of MS (0.84 [95% CI
0.75 – 0.93; P = 0.001]) while adjusting for sex and age. In
the second model, when US-CRP and HOMA-IR were
added to the model, 1-SD of adiponectin remained associ-
ated with a lower prevalence ratio of MS (0.88 [95% CI
0.79 – 0.97; P = 0.012]). The same is true while replacing
HOMA-IR by ISI Matsuda in the model (0.88 [95% CI
0.80 – 0.97; P = 0.011]). Adding separately smoking status,alcohol consumption, physical activity, and waist circum-
ference to this model did not change these results.
São Paulo cohort
We replicated similar models with data from the São
Paulo cohort and observed similar results. In the first
model, 1-SD of adiponectin levels was significantly asso-
ciated with a lower prevalence ratio of MS (0.94 [95% CI
0.90 – 0.97; P = 0.001]) while adjusting for sex and age.
In the second model, 1-SD of adiponectin remained
associated with decreased prevalence ratio of MS (0.93
[95% CI 0.88 – 0.98; P = 0.001]) when HOMA-IR were
added to the model. Adding separately smoking status,
alcohol consumption, physical activity, and waist cir-
cumference to this model did not change these results.
Discussion
The present study assessed the relationship between adi-
ponectin levels and MS in a two-stage study using data
from two cohorts. We demonstrated that lower circula-
ting total and HMW adiponectin levels were associated
with the presence of MS. Decreasing total and HMW
adiponectin plasmatic levels were related with an increa-
sing number of MS criteria in both cohorts. This associ-
ation was independent of age and sex, smoking status,
alcohol consumption, physical activity, waist circumfer-
ence, insulin sensitivity, and subchronic inflammation as
shown while adjusting for confounders in different mul-
tivariate models with data from the Porto Alegre cohort.
In order to confirm these findings, we applied the same
approach in an independent cohort of subjects with differ-
ent clinical characteristics who were being investigated for
coronary artery disease in São Paulo. The confirmation of
the same associations in these two different cohorts would
underscore that this was not a spurious finding. Addition-
ally, total adiponectin levels were lower in the presence of
each MS criterion in the Porto Alegre cohort whereas
similar findings were observed in the São Paulo cohort,
except for the elevated blood pressure and elevated glu-
cose criteria. We found similar findings with HMW adi-
ponectin levels which were lower in the presence of low
HDL-cholesterol and elevated triglycerides criteria. Differ-
ent from total adiponectin, HMW adiponectin levels were
lower in the presence of elevated glucose criterion where-
as their levels were not different in the presence of high
waist circumference criterion. Since HMW adiponectin
levels were inversely related with waist circumference, we
believe that HMW adiponectin levels were not statis-
tical lower in the presence of MS as a matter of sam-
ple size (P = 0.065).
Our results corroborate the findings of other studies
which have analyzed the relationship between adiponec-
tin levels and the MS [6,17]. Vega and Grundy showed
that overweight and obese men with a high adiponectin/
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levels and higher insulin sensitivity than those with a lo-
wer adiponectin/leptin ratio (6). Besides, Mente et al.
suggested a possible causal relationship between low se-
rum adiponectin levels and insulin resistance as measured
by HOMA-IR (15).
As an extension to these studies, our findings suggest
that adiponectin is inversely related to MS ratios while
adjusting for possible confounders. We also tried to ex-
plore the possible factors related to lower adiponectin
levels by the presence of MS. Lower adiponectin levels
were observed with increasing US-CRP and HOMA-IR
whereas higher adiponectin levels were related to in-
creasing insulin sensitivity. Several studies have demon-
strated that adiponectin is related to insulin sensitivity,
since it sensitizes hepatocytes to the effects of insulin,
suppressing hepatic glucose output [18]. Adiponectin
also promotes fatty acid oxidation in the liver and adipo-
cytes, decreasing triglycerides levels [19-22] and increas-
ing glucose uptake by skeletal muscles [23,24].
Central obesity has been related to adipose cell enlarge-
ment and the development of a proinflammatory state
[25]. We have found a significant and inverse correlation
in both cohorts between waist circumference and adipo-
nectin plasma levels. Additionally, low adiponectin levels
were related to high US-CRP, a marker of subchronic in-
flammation. In fact, the hypoadiponectinemia, per se, may
partly determine the proinflammatory state found in sub-
jects with MS in our study, especially those with central
obesity.
The strongest relationship between adiponectin levels
and MS criteria was observed with HDL cholesterol. Some
studies suggest that the association between adiponectin
and HDL cholesterol may result from the effect of adipo-
nectin in reducing triglycerides, apo A-I fractional cata-
bolic rate [26,27], and hepatic lipase activity [28,29].
Although we found that decreasing adiponectin levels
were related to increasing blood pressure in the Porto
Alegre cohort, we were not able to find the same re-
sults in the São Paulo cohort with both, the total and
HMW adiponectin. Additionally, we believe that in São
Paulo, where subjects were investigated for coronary ar-
tery disease by coronary arteriography, a high rate of anti-
hypertensive medications used by this population affected
this relationship by their direct action on adiponectin
levels and by their action on blood pressure.
There are potential limitations to our study. Firstly,
the cross-sectional study design makes it difficult to in-
fer causal relationship between low total and HMW adi-
ponectin levels and MS. Secondly, the subjects are not
representative of the general population, since they were
referred for assessment and evaluation of MS in Porto
Alegre and to coronary artery disease confirmation by
coronary angiography in São Paulo. However, by usingtwo samples with completely different profiles, we were
able to replicate our results which strength the direction
of our findings. Additionally, our study goes in the same
direction of others that have shown an effect of adipo-
nectin in regulating lipid and glucose metabolism, which
corroborates our findings [6,17].
Conclusions
In conclusion, total and HMW adiponectin levels not only
are lower in the presence of MS, but it also decreases by
increasing number of MS criteria. These levels are partly
determined by their relationship with HDL cholesterol, tri-
glycerides and abdominal adiposity. Furthermore, chronic
inflammation and insulin resistance may contribute to the
decrease in adiponectin levels. Longitudinal data of pro-
spective population based studies might be used to under-
stand the role of adiponectin in the development of MS.
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